Table 2.
Results of telephone monitoring and administration of 5-item-questionnaire, echocardiography, cardiopulmonary exercise testing and further evaluation confirming CTEPH
| |
Visit 1, 3 months |
Visit 2, 6 months |
Visit 3, 12 months |
|---|---|---|---|
| N(%) | N(%) | N(%) | |
| Telephone calls |
130 |
102 |
58 |
| 5-Item-Questionnaire positiv |
49 (37.7%) |
26 (25.5%) |
17 (29,3%) |
| Outpatient visits |
49 |
26 |
17 |
| Echocardiography, |
n = 49 |
n = 26 |
n = 16 |
| RVSP >/=35 mm Hg |
10 (20.4%) |
3 (11.5%) |
3 (18.8%) |
| REVSP < 35 mm Hg/ not detectable |
39 (79.6%) |
23 (88.5%) |
13 (81.25%) |
| Cardiopulmonary exercise testing, |
n = 34 |
n = 15 |
n = 9 |
| Abnormal pulmonary perfusion suspected |
12 (35.28%) |
4 (26.7%) |
1 (11.1%) |
| Further evaluation |
21 |
7 |
4 |
| CTEPH/CTPVD proven per visit |
5(3.85)/2(1.5%) |
3(2.94/1(0.98%) |
0/0.0%) |
| CTEPH/CTPVD proven, all patients | 5(3.85%)/2(1.5%) | 8(6.2%)/3(2.3%) | 8(6.2%)/3(2.3%) |
26 months after the start of the program 130 patients had passed 3-months follow-up, 102 patients had completed 6 months follow-up and 58 patients had passed twelve months-follow-up.